AI assistant
Q32 Bio Inc. — Director's Dealing 2025
Feb 27, 2025
34891_dirs_2025-02-26_d83ed6df-9f4b-42e3-953c-49a8419d8e41.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Q32 Bio Inc. (QTTB)
CIK: 0001661998
Period of Report: 2025-02-24
Reporting Person: Iwicki Mark T (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-02-24 | Stock Option (Right to Buy) | $7.29 | D | 37222 | Disposed | 2031-01-21 | Common Stock (37222) | Direct |
| 2025-02-24 | Stock Option (Right to Buy) | $2.54 | A | 37222 | Acquired | 2031-01-21 | Common Stock (37222) | Direct |
| 2025-02-24 | Stock Option (Right to Buy) | $7.29 | D | 7615 | Disposed | 2031-12-16 | Common Stock (7615) | Direct |
| 2025-02-24 | Stock Option (Right to Buy) | $2.54 | A | 7615 | Acquired | 2031-12-16 | Common Stock (7615) | Direct |
| 2025-02-24 | Stock Option (Right to Buy) | $16.82 | D | 25534 | Disposed | 2034-03-24 | Common Stock (25534) | Direct |
| 2025-02-24 | Stock Option (Right to Buy) | $2.54 | A | 25534 | Acquired | 2034-03-24 | Common Stock (25534) | Direct |
Footnotes
F1: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
F2: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
F3: The exercise price of the option is $2.54 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date; provided that in the event (i) the option is exercised prior to the one-year anniversary of the Repricing Date, (ii) the Reporting Person's employment is terminated by the Company prior to the one-year anniversary of the Repricing Date due to Cause (as defined in the 2024 Plan) or (iii) the Reporting Person resigns for any reason prior to the one-year anniversary of the Repricing Date, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted.